Integrative reverse vaccinology approach for identification of a vaccine antigen candidate with immunoprotective and anti-fibrotic potential against Schistosoma japonicum -associated liver fibrosis

Qin Yang, Jue Wang, Ming Ying, Yu Zhang, Li Ping Wong, Hai Yen LeebioRxiv 2025 · DOI

TL;DR

This paper introduces a novel computational pipeline that integrates host single-cell transcriptomics with parasite antigen screening and molecular docking to identify vaccine candidates against Schistosoma japonicum-associated liver fibrosis (SSLF). The approach successfully identified DRE2_SCHJA as a promising candidate with potential dual protective and anti-fibrotic effects by targeting the host protein FYN.

What Problem Does This Paper Address?

Schistosomiasis, particularly Schistosoma japonicum infection, is a major global health issue, with liver fibrosis (SSLF) being a severe and debilitating complication. Currently, there are no licensed vaccines or specific therapies to prevent or treat SSLF. Existing vaccine development efforts have primarily focused on preventing infection rather than addressing the pathological outcomes like fibrosis. This leaves a critical unmet need for interventions that can both prevent infection and mitigate the long-term damage caused by the disease.

Methods

The authors developed an "in-silico" (computational) pipeline to address this challenge. Key components include:

  • Host Single-Cell Transcriptomics: Analyzing liver tissue from infected and control individuals to identify host "hub proteins" that play a central role in fibrosis development. This involved single-cell RNA sequencing (scRNA-seq) followed by Weighted Gene Co-expression Network Analysis (WGCNA) and protein-protein interaction (PPI) network analysis.
  • Parasite Antigen Screening: Utilizing reverse vaccinology principles to screen S. japonicum proteins for immunogenicity and safety. This involved predicting B-cell, T-cell (CTL and HTL), and allergenicity/toxicity profiles.
  • Structure-Based Modeling (Molecular Docking): Predicting the interaction strength and binding modes between identified parasite antigens and host fibrosis-related hub proteins. This was done using tools like ClusPro and Maestro.

This integrated approach aims to identify vaccine candidates that not only elicit an immune response but also potentially modulate the host's fibrotic pathways.

Datasets

  • Single-cell RNA sequencing data: Publicly available dataset (PRJNA998927) from liver tissues of S. japonicum-HBV co-infected, HBV-induced fibrosis, and healthy control samples.
  • Parasite protein databases: UniProt was used to retrieve S. japonicum proteins.
  • Host protein structures: Obtained from UniProt and AlphaFold models for docking.

Key Insights and Ideas

  • Host-pathology integration is crucial for vaccine design: The study highlights that simply targeting parasite antigens for immune response might not be enough. Incorporating host pathology (like fibrosis) into the antigen selection process can lead to more effective vaccine candidates.
  • FYN as a central regulator of fibrosis: The analysis identified FYN, a Src family tyrosine kinase, as a key upstream regulator in the fibrotic process, linking T-cell receptor signaling to hepatic stellate cell activation and extracellular matrix remodeling.
  • DRE2_SCHJA's dual potential: The parasite antigen DRE2_SCHJA, an Anamorsin homolog involved in iron-sulfur (Fe-S) cluster assembly, emerged as a top candidate. Its interaction with FYN suggests it could not only induce protective immunity but also modulate fibrotic signaling.
  • Novel binding mechanism: DRE2_SCHJA's interaction with FYN's SH2 domain differs from known inhibitors like Saracatinib (which targets the ATP-binding pocket), suggesting a unique mechanism of action that could be exploited for therapeutic benefit.

Key Results

  • Identification of three fibrosis-related host hub proteins: FYN, BCL2, and AKT3 were identified through single-cell transcriptomics.
  • Prioritization of DRE2_SCHJA as a vaccine candidate: This parasite antigen showed high immunogenicity and safety predictions, and importantly, the strongest predicted interaction with FYN (ΔG = -14.9 kcal/mol).
  • In silico immune simulation: DRE2_SCHJA simulation showed a rapid and coordinated immune response, including strong B-cell and T-cell activation, sustained antibody production, and a Th1-skewed cytokine profile, indicating potential for long-lasting immunity.
  • Structural insights: Docking revealed that DRE2_SCHJA binds to the SH2 domain of FYN, distinct from Saracatinib's ATP-binding site, suggesting a novel mechanism for modulating fibrosis.

Limitations and Future Work

  • Scarcity of S. japonicum samples: The analysis relied on a public dataset that involved co-infection with HBV, which could introduce confounding signals despite filtering.
  • Focus on T cells: While T cells are crucial, other immune and stromal populations warrant further investigation.
  • Curated protein selection: Antigen selection was limited to curated proteins, potentially excluding novel candidates.
  • Experimental validation needed: DRE2_SCHJA is proposed as a vaccine target for the first time, and its functional relevance requires experimental validation, particularly during egg deposition and host invasion. Future work should integrate in vitro and in vivo studies, as well as longitudinal vaccine trials, to establish its translational potential.

Summary updated

Abstract

Abstract Schistosoma japonicum- associated liver fibrosis (SSLF) is a major cause of morbidity in Schistosomiasis, yet no licensed vaccines or specific therapies exist to prevent or treat this complication. Current vaccine development has focused mainly on infection prevention, with limited attention to pathology-driven outcomes such as fibrosis. To address this gap, we developed an in-silico pipeline integrating host single-cell transcriptomic analysis, parasite antigen screening, and structure-based modeling. Single-cell RNA-seq of liver tissues from SSLF and controls identified three fibrosis-related hub proteins: FYN, BCL2, and AKT3. In parallel, parasite antigens curated from public databases were evaluated for immunogenicity and safety using reverse vaccinology principles. Among these, DRE2_SCHJA, an Anamorsin homolog involved in Fe–S cluster assembly, was prioritized as the top candidate. Docking analysis predicted the strongest interaction between DRE2_SCHJA and FYN (ΔG = −14.9 kcal/mol), linking the antigen to a central regulator of fibrosis. Unlike Saracatinib, which inhibits FYN at the ATP–binding pocket, DRE2_SCHJA bound to the SH2 domain through both canonical and non-canonical contacts, indicating a different regulatory mechanism. Taken together, these findings suggest DRE2_SCHJA as a potential vaccine candidate with both protective and anti-fibrotic potential against SSLF. While experimental validation is required, this study supports the early identification of SSLF vaccine candidates in a rapid and cost-effective manner and provides a framework applicable to other neglected tropical diseases. Athor summary Schistosoma japonicum (S. japonicum) is a parasitic disease that remains a major health problem in parts of Asia, especially in China. One of its most harmful consequences is liver fibrosis, which causes long-term illness and reduces quality of life. Currently, there are no drugs or vaccines that specifically prevent or treat this condition. In this study, we used a fast and low-cost computer-based method to search for vaccine targets against liver fibrosis caused by S. japonicum . We identified a parasite protein that could serve as a vaccine target, with the potential to prevent fibrosis from developing and to slow its progression. If future studies confirm its role, such a vaccine could greatly improve the long-term health of people living with schistosomiasis and inspire new strategies for vaccine development in other neglected tropical diseases.
BibTeX
@misc{yang2025integrative,
  author = {Qin Yang and Jue Wang and Ming Ying and Yu Zhang and Li Ping Wong and Hai Yen Lee},
  title = {{Integrative reverse vaccinology approach for identification of a vaccine antigen candidate with immunoprotective and anti-fibrotic potential against <i>Schistosoma japonicum</i> -associated liver fibrosis}},
  year = {2025},
  doi = {10.1101/2025.09.02.673671},
  howpublished = {bioRxiv},
}
Figure